Qube Research & Technologies Ltd Has $2.77 Million Position in Amgen, Inc. (NASDAQ:AMGN)

Qube Research & Technologies Ltd raised its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,052 shares of the medical research company’s stock after buying an additional 225 shares during the period. Qube Research & Technologies Ltd’s holdings in Amgen were worth $2,774,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of AMGN. Norges Bank acquired a new stake in shares of Amgen during the 4th quarter valued at $1,283,248,000. Thoroughbred Financial Services LLC boosted its stake in shares of Amgen by 19,447.3% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 1,805,392 shares of the medical research company’s stock valued at $180,539,000 after buying an additional 1,796,156 shares during the period. Ellis Investment Partners LLC boosted its stake in shares of Amgen by 18,906.7% during the 1st quarter. Ellis Investment Partners LLC now owns 605,934 shares of the medical research company’s stock valued at $605,000 after buying an additional 602,746 shares during the period. Geode Capital Management LLC boosted its stake in shares of Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after buying an additional 482,760 shares during the period. Finally, First Trust Advisors LP boosted its stake in shares of Amgen by 37.3% during the 2nd quarter. First Trust Advisors LP now owns 1,196,708 shares of the medical research company’s stock valued at $220,529,000 after buying an additional 325,404 shares during the period. 78.96% of the stock is owned by institutional investors.

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. reissued a “hold” rating on shares of Amgen in a research note on Friday, August 9th. Morgan Stanley decreased their target price on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a research note on Monday, July 15th. Oppenheimer lifted their target price on shares of Amgen from $210.00 to $230.00 and gave the company an “outperform” rating in a research note on Tuesday, August 13th. Wells Fargo & Co lifted their target price on shares of Amgen from $197.00 to $202.00 and gave the company a “market perform” rating in a research note on Monday, August 12th. Finally, Royal Bank of Canada reissued a “hold” rating on shares of Amgen in a research note on Sunday, August 11th. Nine equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $212.72.

In related news, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the transaction, the director now owns 16,336 shares in the company, valued at approximately $2,990,141.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total transaction of $375,160.00. Following the completion of the transaction, the director now owns 16,336 shares in the company, valued at approximately $3,064,306.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,425 shares of company stock valued at $804,312. 0.25% of the stock is owned by company insiders.

Shares of AMGN stock traded up $4.71 on Friday, hitting $204.02. The company’s stock had a trading volume of 2,922,500 shares, compared to its average volume of 3,881,659. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. Amgen, Inc. has a fifty-two week low of $166.30 and a fifty-two week high of $211.90. The firm’s fifty day moving average price is $183.92 and its 200-day moving average price is $182.82. The stock has a market capitalization of $119.53 billion, a price-to-earnings ratio of 14.17, a P/E/G ratio of 2.34 and a beta of 1.19.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.58 by $0.39. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The business had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the previous year, the business earned $3.83 EPS. Amgen’s quarterly revenue was down 3.1% compared to the same quarter last year. Analysts predict that Amgen, Inc. will post 14.25 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Investors of record on Thursday, August 15th will be paid a $1.45 dividend. This represents a $5.80 annualized dividend and a dividend yield of 2.84%. The ex-dividend date is Wednesday, August 14th. Amgen’s payout ratio is presently 40.28%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: Understanding the different types of bonds

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.